Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.
about
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophySexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
P2860
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ospemifene for the treatment o ...... l benefits in bone and breast.
@en
Ospemifene for the treatment o ...... l benefits in bone and breast.
@nl
type
label
Ospemifene for the treatment o ...... l benefits in bone and breast.
@en
Ospemifene for the treatment o ...... l benefits in bone and breast.
@nl
prefLabel
Ospemifene for the treatment o ...... l benefits in bone and breast.
@en
Ospemifene for the treatment o ...... l benefits in bone and breast.
@nl
P2093
P2860
P356
P1476
Ospemifene for the treatment o ...... l benefits in bone and breast.
@en
P2093
Chiao-Jung Kao
Gregory T Wurz
Michael W Degregorio
P2860
P304
P356
10.2147/IJWH.S39146
P407
P577
2013-09-25T00:00:00Z